Indian Pharmaceuticals Industry

According to a government notification, bulk drugs accounted for 63 per cent of total pharmaceutical imports in the country in 2018-19.

Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222

A dozen of the 30 MPs, who are members of the parliamentary standing committee on home affairs, headed by Congress's Anand Sharma, attended the meeting

Some firms are now considering starting their own distribution centres in major cities

Union Cabinet on March 12 had approved scheme for development of three bulk drug and four medical device parks

Short-term disruptions include high input costs and various operational challenges.

On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.

The total deal size thus will be around $500 mn or around Rs 3,750 crore

India supplies almost 20 per cent of the medicines consumed by the world. Every third tablet in the US market is from India

This comes after a week of economic disruption caused by introducing stringent scrutiny, resulting in shipments originating in China getting held up at Indian ports.

Indigenously developed Bharat Biotech's vaccine candidate Covaxin is entering human trials on Wednesday.

The second of a two-part series examines challenges linked to IPR and monopoly once Covid-19 vaccine is created

The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation.

Price and capacity constraints, however, would be big impediments.

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

Patient recruitment for the tocilizumab combination therapy study will begin this month.

Market research firm AIOCD AWACS has predicted zero growth in the domestic market this financial year.

Once touted as a 'wonder drug', HCQ has been battling global controversies around its safety and efficacy as a prophylactic against the new coronavirus SARS-CoV-2.

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19

ICMR conducting study on presence of antibodies in people, results next week